UP!
 |
|
|
Type
|
Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2007 |
|
Key people
|
Allan Oberman (CEO) |
| Revenue | $318 million |
|
Net income
|
$23 million |
| Website | sagentpharma |
Allan Oberman (CEO)
Sagent Pharmaceuticals is a biopharmaceutical company founded in 2007. The company received series A funding of $53 million, as well as $40 million in two rounds of series B funding. As part of the funding, Zhejiang Hisun Pharmaceutical Co. Ltd made an investment of $10 million in Sagent. In total, the company has raised $153 million in equity capital. In 2011 the company filed for IPO - offering 5,750,000 shares of common stock at a price to the public of $16 per share
The company was acquired by Nichi-Iko Pharmaceutical Co., Ltd in 2016.
In 2010, the company entered a partnership with Actavis to market and supply a number of injectable products.
In 2014, the company announced its intention to acquire Omega Laboratories Limited for $85.3 million
In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.
In 2016, the company made its most notable acquisition to date, when it acquired five Abbreviated New Drug Applications from Teva Pharmaceuticals for $40 million. As part of Teva's acquisition on Actavis Generics, a number of drug portfolios are being sold off. Later in the same year, the company was acquired by Nichi-Iko Pharmaceutical Co., Ltd for $736 million (representing $21.75 per share and a 40% share premium).
Official website
| 2016-07-12 | Downgrade | Raymond James Financial Inc. | Buy to Market Perform | |
| 2016-07-11 | Downgrade | Royal Bank Of Canada | Outperform to Hold | |
| 2016-07-11 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $22.00 to $21.75 |
| 2016-06-17 | Reiterated Rating | Jefferies Group | Hold | $13.00 to $15.00 |
| 2016-06-01 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2016-05-09 | Reiterated Rating | Bank of America | Hold | $13.00 |
| 2016-05-09 | Reiterated Rating | Bank of America Corp. | Hold | $13.00 |
| 2016-05-04 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $18.00 |
| 2016-05-04 | Reiterated Rating | RBC Capital | Outperform | $28.00 to $20.00 |
| 2016-05-04 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 to $22.00 |
| 2016-05-04 | Reiterated Rating | Royal Bank Of Canada | Outperform | $28.00 to $20.00 |
| 2016-05-04 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $23.00 to $22.00 |
| 2016-02-17 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $20.00 to $18.00 |
| 2016-01-12 | Lower Price Target | Deutsche Bank | Buy | $21.00 to $18.00 |
| 2016-01-12 | Lower Price Target | RBC Capital | Outperform | $34.00 to $28.00 |
| 2016-01-12 | Lower Price Target | Deutsche Bank AG | Buy | $21.00 to $18.00 |
| 2016-01-06 | Initiated Coverage | JPMorgan Chase & Co. | Neutral | $20.00 |
| 2015-11-04 | Lower Price Target | Jefferies Group | Hold | $24.00 to $18.00 |
| 2015-10-08 | Reiterated Rating | RBC Capital | Outperform | $34.00 |
| 2015-08-06 | Reiterated Rating | Piper Jaffray | Overweight | $35.00 to $32.00 |
| 2015-08-04 | Upgrade | RBC Capital | Sector Perform to Outperform | |
| 2015-06-06 | Reiterated Rating | Raymond James | Buy | $21.00 |
| 2015-06-06 | Reiterated Rating | Raymond James Financial Inc. | Buy | $21.00 |
| 2015-06-03 | Initiated Coverage | Raymond James | Strong-Buy | $31.00 |
| 2015-04-07 | Initiated Coverage | Deutsche Bank | Buy to Buy | $29.00 |
| 2015-02-20 | Boost Price Target | RBC Capital | Sector Perform | $31.00 to $34.00 |
| 2014-12-17 | Lower Price Target | Jefferies Group | Hold | $33.00 to $27.00 |
| 2014-10-03 | Reiterated Rating | Jefferies Group | Hold | $25.00 to $33.00 |
| 2014-07-31 | Downgrade | Needham | Buy to Hold | |
| 2014-07-31 | Boost Price Target | RBC Capital | Sector Perform | $20.00 to $27.00 |
| 2014-07-31 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $24.00 to $27.00 |
| 2014-07-31 | Boost Price Target | Jefferies Group | Hold | $23.00 to $25.00 |
| 2014-07-31 | Downgrade | Needham & Company LLC | Buy to Hold | $25.00 |
| 2014-07-25 | Downgrade | S&P Equity Research | Buy to Neutral | $25.00 to $28.00 |
| 2014-07-25 | Downgrade | Bank of America | Buy to Neutral | $25.00 to $28.00 |
| 2014-05-15 | Reiterated Rating | Jefferies Group | Hold | $23.00 |
| 2014-05-07 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $22.00 to $24.00 |
| 2014-05-07 | Reiterated Rating | Jefferies Group | Hold | $23.00 |
| 2014-04-29 | Reiterated Rating | Jefferies Group | Hold | $23.00 |
| 2014-04-21 | Initiated Coverage | Jefferies Group | Hold | $23.00 |
| 2014-02-12 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $24.00 to $22.00 |
| 2014-02-07 | Upgrade | Bank of America | Neutral to Buy | $26.00 to $25.00 |
| 2014-01-06 | Initiated Coverage | RBC Capital | Underperform | $22.00 |
| 2012-08-10 | Downgrade | RBC Capital Mkts | Outperform to Sector Perform | $24 to $16 |
| 2011-11-29 | Initiated | Collins Stewart | Buy | $25 |
| 2011-06-23 | Downgrade | Needham | Buy to Hold |
| 2016-07-12 | Downgrade | Raymond James Financial Inc. | Buy to Market Perform | |
| 2016-07-11 | Downgrade | Royal Bank Of Canada | Outperform to Hold | |
| 2016-07-11 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $22.00 to $21.75 |
| 2016-06-17 | Reiterated Rating | Jefferies Group | Hold | $13.00 to $15.00 |
| 2016-06-01 | Reiterated Rating | JPMorgan Chase & Co. | Neutral |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SGNT 3 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| RUSSELL FRANK CO/ | 0.36M |
| CATAPULT CAPITAL MANAGEMENT LLC | 60000 |
| VTL Associates, LLC | 8654 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| MORGAN STANLEY INVESTMENT MANAGEMENT INC | 9.87% (3147052) | SGNT / |
| China Renaissance Capital Investment II GP | 8.71% (2779003) | SGNT / |
| YORDON JEFFREY Chief Executive Officer | 1.93% (616076) | ATNX / SGNT / |
| OBERMAN ALLAN Chief Executive Officer | 0.32% (101986) | SGNT / |
| Logerfo Michael Chief Legal Officer | 0.17% (53292) | SGNT / |
| Patterson Albert Senior VP, Operations | 0.15% (48690) | SGNT / |
| Drake Lorin VP, Sales and Marketing | 0.12% (39172) | SGNT / |
| Singer Jonathon M Chief Financial Officer | 0.12% (38728) | LDR / RTIX / SGNT / |
| KUNG FRANK | 0.12% (36909) | AMRS / SGNT / |
| Vivo Ventures V, LLC | 0.11% (34961) | CAPN / MEIP / SGNT / |
| Vivo Ventures VI, LLC | 0.08% (25320) | SGNT / |
| FLANAGAN ROBERT J | 0.04% (12200) | SGNT / WPC / |
| HUSSEY JAMES M President | 0.03% (11058) | SGNT / |
| BULLOCK DONALD R Executive V.P. Sales | 0.03% (10656) | SGNT / |
| SHEA THOMAS JOSEPH VP, Global Alliance Management | 0.03% (10442) | SGNT / |
| Harmon J Frank EVP, Global Operations | 0.03% (8915) | SGNT / |
| Behrens Mary Taylor | 0.02% (7097) | HMA / SGNT / |
| Krizman Anthony | 0.02% (7097) | SGNT / |
| FEKETE MICHAEL | 0.02% (5651) | SGNT / SPNE / |
| Greve Jeffrey W. Vice President, Controller | 0.02% (4962) | SGNT / |
| Pauli Ronald Chief Financial Officer | 0.01% (3680) | HZNP / SGNT / |
UM